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Abstract
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or
tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent
development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in
clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein-
coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors
have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150
kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug
development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics,
tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the
treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in
relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies.
Keywords: Kinases, Kinase inhibition, Small-molecule drugs, Cancer, Oncology
Background
Kinases are enzymes that transfer a phosphate group to a
protein while phosphatases remove a phosphate group
from protein. Together, these two enzymatic processes
modulate numerous activities of proteins in a cell, often in
response to an external stimulus [1]. Approximately 538
known kinases are encoded in the human genome, and
these kinases maintain cellular function by turning protein
function on, while corresponding phosphatases reverse
this action [2, 3]. These counter mechanisms greatly
improve the plasticity of epigenome by regulating protein
activity in virtually every imaginable way. Biochemically,
protein kinases catalyze the following reaction [3]:
MgATP1− þ protein−O : H→ protein−O
: PO3
2− þMgADPþ Hþ
Recent advances in our understanding of the fundamen-
tal molecular mechanisms underlying cancer cell signaling
have elucidated a crucial role for kinases in the carcino-
genesis and metastases of various types of cancer [4].
Since most protein kinases promote cell proliferation,
survival and migration, when constitutively overexpressed,
or active, they are also associated with oncogenesis [5].
Genome-wide studies of kinase mutations have revealed
genetically inherited variants of specific kinases are caus-
ally associated with cancer initiation, promotion, progres-
sion as well as recurrence [4, 6]. Over the last three
decades, multiple human malignancies have been identi-
fied to be associated with modulation and dysfunction of
protein and lipid kinases and deactivated phosphatases on
account of chromosomal reshuffling and genetic muta-
tions [7–9]. Apart from the oncological issues, dysregula-
tion of kinases has been demonstrated in many human
disorders including immune, neurological and infectious
diseases [10–13]. However, there is probably no greater
clinical niche for kinases as the key targets for developing
drugs than in cancer therapy. Kinome, the complete set of
protein kinases encoded in its genome has become an
attractive target for the treatment of numerous types of
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cancer. Single and multiple kinase inhibitors, both syn-
thetic and natural molecules, are now targeted therapeutic
strategies for treatment of human malignancies. The
ROCK kinase inhibitor fasudil for treating cerebral vaso-
spasms was the first approved small molecule for clinical
use [14]. Kinase inhibitors now account for a quarter of all
current drug discovery research and development efforts.
Key oncogenic kinase drug targets include the PIK3CA,
BRAF, and epidermal growth factor receptor (EGFR),
which activates significant tumor cell signaling pathways
and is related to the mutations and/or deletions in phos-
phatase and tensin homolog (PTEN), a phosphatase that
negatively regulates PI3K [6, 7, 15]. Approximately 538
kinases are encoded in the human genome. Apart from
this wide range of kinase-based drug targets, inhibition of
distinct kinase signaling pathways can be less cytotoxic to
non-cancerous cells, thus presenting the selective killing
of tumor cells with considerably lower toxic manifesta-
tions [16, 17]. Interestingly, specific-kinase inhibitors, cur-
rently in clinical treatments, e.g., imatinib and dasatinib,
produce more favorable outcome compared to conven-
tional cytotoxic therapy [18, 19]. These kinase inhibitors
have achieved a significant increase in patient survival rate
in myeloid leukemia (CML) and gastrointestinal stromal
tumors (GIST), thus translating basic molecular research
into effective patient treatment. Due to improved clinical
efficacy, U.S. Food and Drug Administration (FDA) has
approved many small-molecule kinase inhibitors for clin-
ical use (Fig. 1). These kinase inhibitors include target
kinome members such as EGFR, ERBB2, VEGFRs, Kit,
PDGFRs, ABL, SRC and mTOR, all providing improved
clinical outcome and patient health status [4, 20]. The
majority of these inhibitors target the ATP-binding site
[21, 22], while a few of the non-ATP competitive kinase
inhibitors target novel allosteric sites [23]. Consequently,
the inhibition of kinase activity in treated patients
prompts multiple anti-proliferative mechanisms, which
leads to clinical remission of cancer.
The current procedure for developing robust and select-
ive kinase inhibitors has swiftly evolved from synthesizing
analogs of staurosporine to sophisticated structure-based
design methodologies, facilitated by molecular docking,
crystallography and nuclear magnetic resonance spectros-
copy [24, 25]. Since 2001, more than 10,000 patent appli-
cations for kinase inhibitors have been filed in the United
States alone. In addition to the small-molecule kinase
inhibitors, kinase-targeted antibodies have also demon-
strated efficacy in various cancers, for example, cetuximab
in colorectal and head and neck cancer, and trastuzumab
in breast cancer [26, 27]. Trastuzumab and cetuximab
bind to the extracellular domain of HER2 and EGFR
respectively, and block the binding of the natural ligand,
thus avoiding conformational rearrangement essential to
the activation of the kinase and its downstream kinase-
signaling pathways. Currently, FDA has approved 35 drugs
(31 for cancer therapy) including orally effective direct
protein kinase inhibitors that target a limited number of
enzymes (Table 1). However, despite these encouraging
results, the problems with drug resistance, toxicity, and
compromised efficacy present critical challenges in both
clinical and experimental oncology [3]. Furthermore,
problems in the synthesis of novel kinase inhibitors have
plagued drug development through an inadequate under-
standing of the selectivity of the kinase inhibitors [16, 28].
Fig. 1 Chemical structures of representative kinase inhibitors used for treatment of various human cancers
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A key challenge in the clinical assessment is to identify the
most efficient combination of kinase targets and then de-
velop treatment combinations for targeted cancer. These
issues have prompted research initiatives that may over-
ride various limitation of kinase inhibition, particularly
evading the treatment-related drug resistance. In this
current review, the authors examined the status, novel
methodologies of drug design and validation of the pro-
spective kinase inhibitors for clinical usage.
Role of kinases in cancer
Targeting the kinases harboring oncogenic transform-
ational capacity and metastasis has led to a notable
change in the clinical management of cancer (Fig. 2).
Hundreds of kinases play overlapping and intricate roles
in cell transformation, tumor initiation, survival and pro-
liferation. Diving kinases while justifying their coinciding
functionalities is difficult. However, in order to under-
stand and discuss their oncogenic undertakings, they
can be vaguely categorized based on their hallmark roles
in cancer. The first group is the kinases that play a fun-
damental role in the primary oncogenic transformation
and thus present themselves as prospective drug targets.
Cytoplasmic tyrosine kinases are critical conveyers of
extracellular signals, and mutations in these kinases have
been reported to occur in various oncogenic conditions.
This category includes the PI3K family of dual specific
protein/lipid kinases, which are the most frequently mu-
tated kinases implicated in 30–50% of human cancers
[29]. PI3KCA, perhaps the most notable member of
PI3K family is associated with the pathology of colorec-
tal cancer [30], breast cancer [31], ovarian cancer [32],
endometrial carcinoma [33], and hepatocellular carcin-
oma [34]. The PI3KCA kinase catalyzes the production
of PIP3, a phospholipid which activates downstream sig-
naling components such as protein kinase AKT and pro-
motes tumor cell growth and survival [35]. Similarly,
Table 1 List of FDA-approved kinase inhibitors and their drug
targets
Drug target Protein substrate Drug
ALK Tyrosine Crizotinib, Ceritinib, Alectinib, Brigatinib
BCR–Abl Tyrosine Bosutinib, Dasatinib, Imatinib, Nilotinib,
Ponatinib
B-Raf Serine/threonine Vemurafenib, Dabrafenib
BTK Tyrosine Ibrutinib
CDK family Serine/threonine Palbociclib, Sorafenib, Ribociclib
c-Met Tyrosine Crizotinib, Cabozantinib
EGFR family Tyrosine Gefitinib, Erlotinib, Lapatinib,
Vandetanib, Afatinib, Osimertinib
JAK family Tyrosine Ruxolitinib, Tofacitinib
MEK1/2 Dual specificity Trametinib
PDGFR α/β Tyrosine Axitinib, Gefitinib, Imatinib, Lenvatinib,
Nintedanib, Pazopanib, Regorafenib,
Sorafenib, Sunitinib
RET Tyrosine Vandetanib
Src family Tyrosine Bosutinib, Dasatinib, Ponatinib,
Vandetanib
VEGFR family Tyrosine Axitinib, Lenvatinib, Nintedanib,
Regorafenib, Pazopanib, Sorafenib,
Sunitinib
Fig. 2 Categorization of different kinases implicated in human cancer. CTK: cytoplasmic tyrosine kinase, S/T Kinase: serine/threonine kinase, LK:
lipid kinase, RTK: receptor tyrosine kinase. SK1: Sphingosine kinase 1, PI3K: phosphoinositide 3-kinase, PKCi: Protein kinase Ci, mTOR: mammalian
target of rapamycin, CDKs: cyclin-dependent kinases, ATM: Ataxia telangiectasia mutated, Akt: protein kinase B, S6K: ribosomal protein S6 kinase,
STK11/LKB1: Serine/threonine kinase 11 or liver kinase B1, PLKs: Polo-like kinases, b-Raf: B-Raf proto-oncogene, Aur A & B: Aurora Kinase A & B, c-SRC:
Proto-oncogene tyrosine-protein kinase Src, c-YES: c-Yes proto-oncogene (pp62c-Yes), Abl: Abelson murine leukemia viral oncogene homolog 1, JAK-2:
Janus kinase 2, RON: Recepteur d’Origine Nantais, FGFRs: Fibroblast growth factor receptors, c-Met: c-MET proto-oncogene, c-Ret: c-RET proto-oncogene,
IGF-IR: Insulin-like growth factor 1 receptor, EGFR: Epidermal growth factor receptor, PDGFR-α: Platelet-derived growth factor receptor α, c-Kit: proto-oncogene
c-Kit or Mast/stem cell growth factor receptor, Flt3,Flt-4: Fms-like tyrosine kinase 3, 4, PDGFR-β: Platelet-derived growth factor receptor β, ALK: Anaplastic
lymphoma kinase, HER-2: human epidermal growth factor receptor-2
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active form of the protein kinase Akt/PKB contributes
to oncogenic transformation of cells [36]. Likewise,
V599E and V600E mutations in BRAF kinase are associ-
ated with various carcinomas while BRAF somatic mis-
sense mutations occur in 66% of malignant melanomas
[37]. The oncogenic mutations in JAK2 kinase such as
single point mutation (Val617Phe) and JAK2 exon 12
mutations are implicated in both myeloproliferative dis-
orders and myelodysplastic syndromes [38, 39]. Simi-
larly, genetic alterations in other kinases such as ALK,
IGF-1R, c-Kit, FGFR1–4, c-Met, c-Ret, c-SRC, regulate
fundamental molecular mechanisms for tumor cell
growth and development [9, 40]. Apart from tumor initi-
ation, kinases are also vital for tumor cell survival and
proliferation and may be present as downstream mem-
bers of oncogenic kinase pathways. This category of
kinases includes EGFR, a receptor tyrosine kinase, which
has been shown to prevent autophagic cell death by
maintaining intracellular glucose levels through inter-
action and stabilization of the sodium/glucose cotran-
sporter 1 (SGLT1) [41]. Oncogenic alterations in EGFR
make up approximately 45% of mutations in the tyrosine
kinase domain [42, 43]. This leads to the loss of the
inhibitory regulatory domains for dimerization resulting
in hyper-proliferation of cancer cells via G1/S cell cycle
progression [44, 45]. Other crucial members of the
kinase family are aurora kinases (Aurora A-C). Aurora
kinases are strategic kinases involved in defective spindle
pole organization, and their pathophysiology correlates
strongly with their oncogenic functions [46]. Aurora-A
is an oncogenic kinase, and its amplification is docu-
mented in 10–25% of ovarian cancers [47]. Interestingly,
Aurora A gene was originally named BTAK (breast
tumor activated kinase) because its mRNA is overex-
pressed in breast cancer and is involved in the oncogenic
transformation of breast cells [48]. Aurora A phosphory-
lates p53 at Ser215 and inhibits p53-DNA binding, dis-
rupting cell cycle check activities [49]. It is also related
to the activation of NF-κB, which boosts cancer cell sur-
vival by evading apoptosis [50]. Similar to Aurora-A,
Aurora B and C are overexpressed in tumor cells and
help cell survival, metastasis, and avoidance of apoptosis
[51–53]. Other examples of tumor cell survival kinases
include MEK1 [54], MEK2 [54], mTOR [55], and S6 kin-
ase [56] which are all downstream members of MAPK,
PI3K–Akt and EGFR pathway, respectively. In recent
years, the mechanistic basis for developing kinase inhibi-
tors from the second class of kinases has improved sig-
nificantly. Types of serine/threonine kinases include
MAP kinases (activated by protein phosphatases), ERK
and stress-activated JNK and p38. Currently, there are
about 30 Aurora kinase inhibitors in different stages of
pre-clinical and clinical development [57]. The third cat-
egory of kinases implicated in oncogenesis includes
kinases overexpressed in tumors and surrounding tissues
of cancers, which are important for the maintenance of
tumors in the host. These include mutations in neuro-
trophic growth factor receptor which are involved in pilocy-
tic astrocytoma, the most common childhood brain tumor
[58]. Other examples include VEGFRs, fibroblast growth
factor receptor (FGFR) kinases, protein kinase CK2 and
TrkB [9, 16]. Overall, oncogenic kinases underlie and define
multiple features of cancer including rapid proliferation,
survival, growth, and metastasis, and have promoted the
development of a plethora of kinase inhibitors. The fourth
category of kinases, RTK with 58 known members and 20
subfamilies, were discovered more than a quarter of a cen-
tury ago [40]. These kinases have a similar molecular archi-
tecture, and their mutations and aberrant activation are
associated with carcinogenesis and angiogenesis. Four prin-
cipal mechanisms are involved in abnormal RTK activation
in human cancers; these include autocrine activation,
chromosomal translocations, RTK overexpression, and
gain-of-function mutations. RTKs are activated by growth
factor binding by inducing receptor dimerization or in
some cases subset of RTKs forms oligomers even in the
absence of activating ligand [59, 60]. Principal members of
RTK include 20 members including EGFR and others [61].
EGFR represent RTKs family as the well-studied kinase,
implicated in several human cancers including lung cancer
[62], glioblastoma [63], breast cancer [64], cervical carcin-
oma [65] and related mutations [66]. Several small-
molecule inhibitors and monoclonal antibodies have been
approved by FDA against RTKs for cancer therapy. The key
drugs include Imatinib (against PDGFR, KIT, Abl, Arg),
Sorafenib (against Raf, VEGFR, PDGFR, Flt3, KIT) and
Lapatinib (against EGFR, ErbB2).
Kinase discovery and development timeline
The development of kinase inhibitors for the treatment of
human cancers started in mid 1970s (Fig. 3). In 1978, the
first oncogene was found to be a protein kinase [67]. This
discovery was supported by a successive finding in 1981
when tumor-promoting phorbol esters was shown to
exhibit hyperactivation of protein kinase C (PKC) [68]. In
the coming years, naphthalene sulphonamides, the first
protein kinase inhibitors were synthesized and served as a
basic design for developing further molecules [69]. During
this time, staurosporine, an antifungal drug was shown to
be a nanomolar inhibitor of PKC [70]. This drug was later
used as a parent compound to produce various analogs as
potential inhibitors of PKC. In the 1991 the 3-D structure
of protein kinase A (PKA) was elucidated, and it became
apparent that the residues that were involved in binding
ATP were conserved from kinase to kinase [71, 72]. This
discovery perpetuated a myth that it was “impossible” to
develop protein-kinase inhibitors with the requisite
potency and specificity. However, with the discovery of
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cellular targets for cyclosporin and subsequent develop-
ment of HA1077, an inhibitor of several protein kinases,
the field of kinase inhibitors rapidly progressed [14, 73, 74].
Finally, the breakthrough occurred in 2001 when imatinib,
a phenyl-amino-pyrimidine derivative targeting the
inactive conformation of the ABL1 kinase, was approved
for the treatment of CML (Fig. 4). Starting with a 2-
phenylaminopyrimidine derivative, chemists added a 3′
pyridyl group, benzamide, a flag methyl instead of N-
methylpiperazine to synthesize a drug candidate called
CGP57148B (later changed to imatinib) [75]. Clinical
targeting of BCR-ABL gene, formed by the fusion of ABL
gene from chromosome 9 to the BCR gene on chromo-
some 22, also called the Philadelphia chromosome,
improved the clinical management of leukemia patients
[76, 77]. Owing to its’ broad-spectrum nature imatinib has
since then been approved for various other oncology indi-
cations. Following the FDA approval of imatinib, different
strategies have been used for the development of single
and multi-target kinase inhibitors for cancer treatment
[78]. More active drugs, such as nilotinib, with a selectivity
profile similar to imatinib, were approved for imatinib-
resistant CML [79, 80]. Later on, the indolinone-derivative
sunitinib with a broad spectrum activity targeting VEGFR,
PDGFR, FGFR, KIT, and FLT3, was approved for the
treatment of renal cell carcinoma, as well as second-line
therapy in the imatinib-resistant gastrointestinal stromal
tumor (GIST) [81]. Sorafenib was later approved for the
treatment of renal cell and hepatocellular carcinoma due
to its ability to bind to the inactive conformation of the
VEGFR kinase [82]. Similarly, in the year 2009, pazopanib,
a 2-amino pyrimidine targeting VEGFR, PDGFR, and KIT
was approved for the treatment of advanced renal cell car-
cinoma [83]. A quick surge in clinical approval of kinase
inhibitors started following the approval of everolimus
(mTOR inhibitor) in 2009 for the treatment of metastatic
renal cell carcinoma (mRCC), astrocytoma and breast
tumors [84–86]. In the year 2011, four kinase inhibitors,
vemurafenib, vandetanib, ruxolitinib, and crizotinib were
approved for the treatment of melanoma, thyroid cancer,
myelofibrosis and ALK-positive non-small cell lung cancer
[87–90]. Successively, in 2012 and 2013 ten new kinase
inhibitors were approved by FDA for the treatment of
various malignancies. Since the initial development of
Fig. 3 Timeline of key events in the development of protein-kinase inhibitors for the treatment of cancer
Fig. 4 Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib mesylate)
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imatinib, 28 kinase inhibitors have been approved by FDA
with Brigatinib and Osimertinib being the latest approvals
[91, 92]. Apart from the approved kinase inhibitors, there
is more than three thousand ongoing Phase I-III clinical
trials for hundreds of new kinase inhibitors. It is therefore
beyond the scope of this mini-review to discuss all the
protein kinase inhibitors that are in clinical Phase I–III.
Types of kinase inhibitors
Kinase inhibitors are very efficacious for the treatment of
cancer especially targeting specific mutations that chiefly
drive tumorigenesis. They are categorized according to
their capacity to catalyze the transfer of the terminal phos-
phate of ATP to the substrates that usually contain a
serine, threonine or tyrosine residue (Table 2). Many
reviewers have categorized types of kinase inhibitors
according to their mechanism of action. Initially, small
molecule protein kinase inhibitors were divided into three
classes, termed as types I, II, and III kinase inhibitors [93].
Dar and Sakot defined the type I kinase inhibitor as “a
small molecule that binds to the active conformation of a
kinase in the ATP pocket,” the type II inhibitor as “a small
molecule that binds to an inactive (usually Asp-Phe-Gly
(DFG)-OUT) confirmation of a kinase,” and the type III
inhibitor as “a non-ATP competitive inhibitor” or
allosteric inhibitor [93, 94]. Later on, Zuccotto et al. intro-
duced a new class of kinase inhibitors, i.e. type I½ inhibi-
tors, which bind to the protein kinases with the DFG-Asp
in and C-helix out conformation [95]. Later, Gavrin and
Saiah further divided the allosteric effectors into two sub-
classes (III and IV) where the type III inhibitors bind
within the cleft between the small and large lobes adjacent
to the ATP binding pocket and type IV inhibitors bind
outside of the cleft and the phosphor-acceptor region [96].
Afterwards, bivalent molecules that span two regions of
the protein kinase domain were labeled as type V inhibi-
tors [97]. Finally, small molecules that form covalent
adducts with the target enzyme were recently termed as
covalent inhibitors [94]. The classification described
herein uses these parameters with added subdivisions and
criteria, labeling them as types I, II, allosteric, and sub-
strate directed and covalent inhibitors.
Type I kinase inhibitors
Type I kinase inhibitors represent ATP-competitors that
mimic the purine ring of the adenine moiety of ATP.
Functionally, they interact with the conformational phos-
phorylated active catalytic site of the kinases. These kinase
inhibitors bind to the active conformational site and alter
the structural conformation otherwise favorable to phos-
photransfer [98, 99]. Type I inhibitors usually contain a
heterocyclic ring system that occupies the purine binding
site, where it serves as a scaffold for side chains that
occupy adjacent hydrophobic regions [100]. These hydro-
philic regions of the enzyme occupied by the ribose
moiety of ATP may be used to exploit the solubility of the
drugs or other active compounds [98]. To date, many
Type I kinase inhibitors for the treatment of cancer have
been approved by the FDA viz. bosutinib, crizotinib, dasa-
tinib, erlotinib, gefitinib, lapatinib, pazopanib, ruxolitinib,
sunitinib, and vemurafenib. Apart from the large-scale
clinical success, Type I kinase inhibitors also come with
adverse side-effects. Type I inhibitors display an inclin-
ation for low kinase selectivity as the targeted ATP pocket
is conserved through the kinome; therefore, increasing the
potential for off-target side effects. This little selectivity
for targeted kinases may result in cardiotoxicity and pos-
sible deterioration in cardiac function [101, 102].
Type II kinase inhibitors
Type II kinase inhibitors act by targeting the inactive con-
formation of kinases and interact with the catalytic site of
the unphosphorylated inactive conformation of kinases
[103]. Type II kinase inhibitors exploit new interactions
inside the lipophilic pocket derived from the change of con-
firmation of the phenylalanine residue of the “Asp-Phe-Gly
(DFG)” N-terminal loop conformation of kinases [16, 103].
These inhibitors interact reversibly with the target kinase
which leads to the formation of single or multiple hydrogen
bonds with the protein in the ‘hinge region’ and also
causes extra interactions in the open DFG-out conform-
ation [98, 103]. These lipophilic interactions have a high
degree of selectivity towards unwanted kinases affecting
an increase in the safety profile of Type II kinase inhibi-
tors. Type II inhibitors also display a high conservation of
Table 2 Classification of small molecule kinase inhibitors
Class of Kinase Inhibitor Mechanism of Action Examples
Type I Competes for the substrate and binds in the ATP-binding pocket of the
active conformation
Bosutinib, Cabozantinib, Ceritinib, Crizotinib,
Gefitinib, Pazopanib, Ruxolitinib, Vandetanib
Type II Type II inhibitors bind to the DFG-Asp out protein kinase conformation,
which corresponds to an inactive enzyme form
Imatinib, Sorafenib, Axitinib, Nilotinib
Type III (Allosteric Inhibitor) Occupy a site next to the ATP-binding pocket so that both ATP and the
allosteric inhibitor can bind simultaneously to the protein.
Trametinib, GnF2
Type IV (Substrate Directed
Inhibitors)
Undergo a reversible interaction outside the ATP pocket and offer
selectivity against targeted kinases
ONO12380
Type V (Covalent Inhibitor) Bind covalently (irreversible)to their protein kinase target Afatinib, Ibrutinib, HK1–272
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distinctive H-bond pattern between the inhibitor and the
glutamic and aspartic acids of the kinase [98, 104]. Due to
the exclusivity of inactive protein kinase conformations, it
was theorized than type II kinase inhibitors would be
more selective. However, there is considerable overlap of
selectivity between type I and type II inhibitors. The dis-
covery of Type II kinase inhibitors such as imatinib and
sorafenib was serendipitous, and it wasn’t until much later
that their mode of action was discovered. The role of ima-
tinib in the consequent development of small molecule
protein kinase inhibitors cannot be overstated. All Type II
inhibitors share a similar pharmacophore and hydrogen
bonds that interact with DFG-out kinase conformational
structure as revealed by the discovery of the Type II kinase
inhibitor co-crystal structure [105]. Since canonical ATP-
binding sites of activated kinases, the target sites of Type I
inhibitors, do not share these features, this pocket is con-
served to a lesser extent across the kinome, and hence
promises better prospects for the rational design of select-
ive inhibitors [100, 103]. Overall, Type II kinase inhibitors
display high selectivity towards kinase inhibition as com-
pared to Type I kinase inhibitors along with the profound
impact on cellular activity.
Type III or allosteric inhibitors
The third class of kinase inhibitors bind outside the
catalytic domain/ATP-binding site and modulates kinase
activity in an allosteric manner. Some authors have
divided the allosteric inhibitors into two subtypes where
type A inhibitors bind to an allosteric site next to the
adenine-binding pocket whereas the type B inhibitors
bind elsewhere [97]. Overall, Allosteric or Type III
inhibitors exhibit the highest degree of target kinase
selectivity as they exploit binding sites and physiological
mechanisms that are exclusive to a particular kinase
[106]. With respect to ATP, these drugs are steady-state
noncompetitive or uncompetitive inhibitors because
ATP cannot prevent their interaction with the target
kinase. One of the earliest allosteric inhibitors was CI-
1040, an orally active, highly specific, small-molecule
inhibitor of the MEK1/MEK2 pathway [107]. A recent
chemical proteomics study confirms the allosteric activ-
ity of type III inhibitors as they showed a higher selectiv-
ity, but also stated that these are special cases as most of
them are designated MEK1/2 inhibitors that bind to a
particular cavity adjacent to the ATP-binding site [108].
Another allosteric kinase inhibitor GnF2 binds to the
myristate binding site of BCR–ABL1 [109]. GnF2 also
displays sound IL-3 reversible anti-proliferative and
apoptotic effect on two mutants identified as E255V and
Y253H [109]. Likewise, TAK-733 binds to the MEK1-
ATP complex in the gate area and the back cleft adjacent
to the ATP-binding pocket; however, it cannot bind to
the adenine pocket owing to its occupation by ATP
[110]. Other examples include RO0281675 and analogs
thereof [111, 112]. Overall, targeting kinases using allo-
steric inhibitors is thought to be a crucial approach for
overcoming hurdles in kinase inhibitor research, such as
limited selectivity, off-target side effects, and drug resist-
ance. In future, more active and target specific allosteric
inhibitors will be discovered as larger stress is placed on
cell-based assays in which kinases are explored in their
native cellular context.
Substrate-directed inhibitors
These are also called Type IV kinase inhibitors and
undergo a reversible interaction outside the ATP pocket,
located in the kinase substrate-binding site. These inhib-
itors don’t compete with ATP and offer a higher degree
of selectivity against targeted kinases [113]. Substrate-
directed inhibitors include ATP-noncompetitive inhibi-
tors such as ON012380 which are targeted against Phila-
delphia chromosome-positive leukemias [114]. More
importantly, ON012380 was found to override imatinib
resistance at physiologically relevant concentrations of <
10 nM [115].
Type V or covalent inhibitors
The covalent kinase inhibitors form an irreversible cova-
lent bond with the kinase active site and target a catalytic
nucleophile cysteine within the active site of the enzyme
[116, 117]. The chemical rationale for developing Type V
inhibitors is based on exposed cysteine side chain in the
ATP site which can be targeted for covalent reaction with
a drug candidate with an electrophilic Michael acceptor in
the right position [118, 119]. This type of kinase inhibition
takes place via trapping of a solvent-exposed cysteine resi-
due either by SN2 displacement of a leaving group or by
reacting with a Michael acceptor incorporated within the
kinase inhibitor [113, 120, 121]. Covalent inhibitors target
respective kinase by formation of a rapidly reversible colli-
sion complex followed by an irreversible enzyme-inhibitor
complex [122]. Afatinib (targets EGFR (ErbB1), ErbB2,
and ErbB4) and ibrutinib are currently FDA-approved
drugs that form a covalent bond with their target kinase.
Afatinib, unlike the first-generation EGFR-TKIs such as
gefitinib and erlotinib, is a mutant-selective EGFR inhibi-
tor with low toxicity profile despite its irreversible mech-
anism [123]. Similar to Afatinib, ibrutinib also targets
mutant-EGFR kinase with a distinct binding conformation
[124]. Both of these kinase inhibitors initiate Michael reac-
tion with the addition of a nucleophile (the -SH of cyst-
eine) to an α, β unsaturated carbonyl compound [125].
C481 within hinge region of the Bruton tyrosine-protein
kinase is hypothesized to form a covalent link with ibruti-
nib [126]. A recently approved kinase inhibitor, neratinib
(HKI-272), inhibits Herceptin-2 (HER-2), and prevents re-
currence in patients with early-stage HER2-positive breast
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cancer [127]. Overexpression of HER-2 is seen in 25–30%
of breast cancer patients and predicts a poor outcome in
patients with primary disease. Likewise, CL-387785, a co-
valent inhibitor, overcomes resistance caused by T790 M
mutation of the epidermal growth factor receptor (EGFR)
[128]. These kinase inhibitors also display an extended
dissociation half-life which minimizes off-target side ef-
fects [118]. Other advantages include prolonged pharma-
codynamics, suitability for rational design, high potency,
and ability to validate pharmacological specificity through
mutation of the reactive cysteine residue [119]. The
approved covalent kinase inhibitors (Ibrutinib, Afatinib,
and Neratinib) have shown that small molecules contain-
ing weak reactive electrophiles can be mutant specific in
action with low toxicity. These kinase inhibitors have initi-
ated resurgence of interest in covalent inhibitors, and
feature an acrylamide functionality to specifically target
the cysteine side chains of kinases. Example include a
recent study showing nine irreversible EGFR and two
BTK inhibitors with higher kinase inhibitory selectivity
than reversible compounds [108]. The Type V or covalent
kinase inhibitors have substantial potential for exploration
as 200 different kinases have a cysteine chain located near
the ATP pocket.
Biochemical mechanism
Biochemically, kinase inhibitors are classified according
to the activation state of the protein kinase target in-
cluding the nature of DFG-Asp (active in, inactive out),
the C-helix (active in, inactive out), and the regulatory
spine (active linear, inactive distorted). Apart from type
III or allosteric inhibitors, all the FDA-approved kinase
inhibitors form hydrogen bonds with one or more hinge
residues. Overall, most kinase inhibitors form: (i) hydro-
phobic contacts with catalytic spine residues; (ii) contact
with the RS3 R-spine residue within the C-helix; (iii)
interaction with the gatekeeper residue; and (iv) residues
that occur just before the DFG-D of the activation seg-
ment [94, 129]. The following section briefly discusses
the biochemical mechanism of action of FDA-approved
kinase inhibitors.
Frequent mutations in various protein kinases present
specific kinase inhibition as a therapeutically relevant
approach in oncology. Kinase inhibitors have evolved to
target many different regulatory and inhibitory mecha-
nisms. There are various mechanisms by which kinase
inhibitors bind to their target kinases broadly classified
into kinase inhibitors that bind either covalently or non-
covalently to or around the ATP binding site. Primarily,
kinases bind with ATP in a cleft between the N- and C-
terminal lobes of the kinase domain. In this domain, the
adenine group of ATP is bound by two hydrophobic sur-
faces and interact via hydrogen bonds to the connector of
two lobes, called the “hinge region” [130–132]. The cleft
of ATP contains various elements such as the flexible acti-
vation loop (A-loop), along with closed conformations
which are responsible for the catalytic activity of the
kinase [133, 134]. The active or inactive state of the pro-
tein kinase is determined by the position of the A-loop,
including the DFG motif at its N-terminal, which has vari-
ous conformations [28, 98, 134, 135]. The only component
of kinases that does not vary between the active and
inactive states is the catalytic loop. The active state of the
protein kinase when the Asp in the DFG motif coordi-
nates one magnesium ion, which prepares the phosphates
of ATP for the transfer of the phosphoryl group. The Phe
in the DFG motif packs under the helix-C positioning
both helix-C and A-loop for catalysis [98, 133, 136].
Protein kinases return to their inactive conformation once
kinase transfers the phosphoryl group from ATP to tyro-
sine, serine or threonine of the substrate protein. This
process also involves the returning of the A-loop to the
closed position by the change of A-loop from the DFG-in
to the DFG-out conformation [98, 137, 138]. However,
ribose binding and the phosphate binding site of ATP
usually remains unexplored by the majority of kinase in-
hibitors [134, 139]. Based on the biochemical mechanisms
of action, kinase inhibitors are categorized as covalent and
non-covalent kinase inhibitors. The non-covalent kinase
inhibitors are classified into those who either bind or do
not bind to the hinge region of the kinase [140]. The
DFG-in or Type I kinase inhibitors bind to hinge region
and represent the vast majority of non-covalent kinase
inhibitors [98]. In these kinase inhibitors, the Asp in the
DFG motif coordinates the phosphates of ATP, and the
Phe in the DFG motif stabilizes the position of helix-C
and the A-loop for catalysis [20]. However, the ATP-
binding pocket is highly preserved among members of the
kinase family, and it is hard to find highly selective Type I
kinase inhibitors. Moreover, the pre-clinical to clinical
translation of Type I kinase inhibitors is hindered as they
compete with high levels of intracellular ATP leading to a
discrepancy between biochemical and cellular analysis.
Contrary to the Type I inhibitors, Type II inhibitors bind
to the DFG-out confirmation of kinases. These inhibitors
induce a conformational shift in the target enzyme such
that the target kinase is no longer able to function. Type II
inhibitors use an additional hydrophobic pocket adjacent
to the ATP site exposed by the movement of A-loop from
DFG-in to DFG-out conformation [141]. This gives the
Type II inhibitors higher selectivity as they recognize
novel regions of the active cleft outside the highly con-
served ATP-binding site. Like Type II kinase inhibitors,
the allosteric inhibitors or Type III inhibitors also display
high selectivity as they explore binding sites and regula-
tory mechanisms that are unique to a particular kinase.
They contain a heterocyclic system that forms one or two
hydrogen bonds with the kinase hinge residue. Like Type II
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inhibitors, they also induce the DFG-out confirmation and
move phenylalanine side chain to a new position [98, 99].
Examples include compounds such as CI-1040, which
inhibit MEK kinase by occupying a pocket adjacent to the
ATP-binding site [107]. Interestingly, exploration of allo-
steric kinase inhibitors also helps to recognize unique
kinase activation targets, which could be explored for thera-
peutic intervention in other diseases states. Recently, there
has been an increased interest in the development of irre-
versible (covalent) kinase inhibitors that form covalent
bonds with cysteine or other nucleophilic residues in the
ATP-binding pocket. These inhibitors have typically been
developed by incorporation of an electrophilic moiety into
an inhibitor that already possesses submicromolar binding
affinity to the target of interest. The covalent kinase inhibi-
tors bind to a cysteine residue in or around the active site,
thus preventing the binding of ATP to the protein kinase
[117, 127]. These kinase inhibitors undergo the “Michael
reaction”, which is a reaction that triggers the addition of a
nucleophile, such as a cysteine, to an α, β unsaturated car-
bonyl functionality. Nucleophile additions cause the forma-
tion of adducts at the electrophilic β-position and inactivate
kinases by irreversibly blocking the binding of ATP to
kinase [142]. These kinase inhibitors are highly selective as
they overcome endogenous ATP competition and target a
specific cysteine at the corresponding position in a kinase.
Various covalent kinase inhibitors target kinases such as
BTK [143], Fes [144], VEGF-R2 [145], and RSK2 [146]
through their ability to bind to a cysteine residue.
Recent clinical developments
Traditional cancer therapies follow palliative as well as
off-targeted approaches in oncology. In contrast, kinase
inhibitors symbolize a class of targeted cancer therapeutic
agents with limited nonspecific toxicities. So far, 28 inhibi-
tors with activity targeted to one or multiple kinases have
been approved for clinical use. With over 500 members,
the kinase family has received a high degree of attention
from academic researchers as well as pharmaceutical in-
dustries [147]. After the clearance of possible hindrances,
owing to the high degree of active site similarities and pos-
sible off-target activity, kinase inhibitors have gained
scientific limelight [21, 24, 78, 148, 149]. In a 13-year
summary of targeted therapies including kinase inhibitors,
the clinical success rate of kinase inhibitors was superior
to other cancer therapies [150, 151]. Nevertheless, this
clinical success does come with exceptions; attempts to
control cytotoxicity during treatment, particularly with
sunitinib and EGFR/VEGF-system targeting drugs have
yielded disappointing results [152–155]. Overall, during
the last 5 years, Aurora kinases [156], casein kinase II
[157], cyclin-dependent kinases [158], focal adhesion
kinase [159], protein kinase B [160], phosphatidylinositol
4,5-bisphosphate 3-kinase delta and gamma [161], polo-
like kinase I [162], tyrosine-protein kinase SYK [163], high
affinity nerve growth factor receptor family [164] and
Wee1-like protein kinase [165] have been targeted in
Phase I clinical trials. Although recent developments have
shown Aurora kinases as major new targets in kinase
inhibitor development [166, 167]. After initial hurdles,
two compounds palbociclib and ribociclib have passed the
phase III clinical trials and are in clinical use [168].
Recent kinase developments include precision therapy
based on tumor genomic data. The ability to perform gen-
etic studies of tumors and follow-up treatment decisions
based on the identification of tumorigenesis drivers has
resulted in significant benefits for patients in need of
effective systemic therapy. The detailed information
regarding all the clinical trials is out of the scope of this
mini-review; however, a few important developments are
highlighted. A small number of small molecule tyrosine
kinase inhibitors have recently received FDA approval for
treatment of non-small cell lung cancer (NSCLC) with
EGFR mutations or ALK translocations [169]. Afatinib, a
second-generation, non-competitive kinase inhibitor tar-
geting all members of the ErbB family of receptors (also
known as Her-2/neu) was approved in 2013 as frontline
therapy for NSCLC patients with EGFR-deletion 19 and
L858R mutations [170]. Despite several challenges that
need to be overcome, reviewed in [171, 172], precision
medicine has yielded important dividends for patients
with advanced cancers [173]. In order to counter currently
undruggable targets and acquired resistance, immunother-
apy has gained widespread recognition in recent years
[174]. Additionally, kinase targeted antibody therapy for
hematological malignancies, and solid tumors have become
established over the past 20 years. Key examples of anti-
body constructs targeting kinases include Trastuzumab and
T-DM1 (targeting ERBB2/HER2) in breast and bladder can-
cer [175, 176], Bevacizumab (targeting VEGF) in ovarian,
metastatic colon cancer and glioblastoma [177], Cetuximab,
Panitumumab and necitumumab (targeting EGFR) in
colorectal cancer and NSCLC [178]. Other experimental
candidates include scFv, affibody and minibody (ERBB2/
HER2 and FGFR1) [179–182], Protein–Fc (VEGFR1 and
VEGFR2) [183] and Intact IgG (EGFR, ERBB2, and VEGF)
in breast and lung cancer studies. Also, there is an
increased development of PI3K and mTOR inhibiting
compounds. Dual PI3K/mTOR inhibitors in advanced clin-
ical trials include NVP-BEZ235 (glioblastomas) [184],
XL765 (breast cancer) [185], GDC0980 (mRCC) [186],
PF04691502 (breast cancer) [187], GSK2126458 (colorectal,
breast, non-small cell lung, and pancreatic cancers) [188],
Quinacrine (various leukemias) [189, 190] and PKI587
(advanced solid malignancies) [191]. Also, buparlisib and
idelalisib, both PI3K inhibitors, have entered phase III clin-
ical trials [192, 193]. In line with PI3K/mTOR inhibitors,
various kinase inhibitors have entered into clinical trials for
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gastrointestinal cancers [194], thyroid carcinoma [195],
breast cancer [196], and endocrine tumors [197]. Many pre-
viously approved kinase inhibitors are being tested in clin-
ical trials against BRAF and cyclin-dependent kinases 4/6
mutations [20, 99]. BRAF somatic mutation, particularly
BRAF V600E/K, drive tumorigenesis through constitutive
activation of the downstream MAPK pathway [198]. Mul-
tiple drugs including vemurafenib, dabrafenib, PLX3603,
ARQ736, CEP-32496, BMS-908662, BGB283, encorafenib
in combination with other chemotherapies are being tar-
geted for BRAF-mutated cancers [199]. It is now suggested
that dabrafenib, a selective BRAF inhibitor may target other
kinases indicating polypharmacology (that is, drugs that act
on more than one target) [108]. A paper published by
Klaeger and colleagues explains the potential of 243 clinic-
ally evaluated kinase drugs [108]. Although multiple new
kinases have been targeted during the last 5 years, a large
share of the cancer kinome is still untargeted. Furthermore,
use of these targeted therapies is not without limitations.
Reservations on the use of kinase inhibitors include the
development of resistance and the lack of tumor response
in the general population and these constraints still need to
be resolved.
Natural bioactives as kinase inhibitors
Overexpression of kinases is observed in multiple carcin-
omas. In recent years, there has been a major paradigm
shift in discovery and screening of natural compounds as
potential kinase inhibitors. Emerging data has revealed
numerous mechanisms by which natural compounds miti-
gate kinase mutations. Classically, many of the biological
actions of small molecule compounds, especially polyphe-
nols, have been credited with their antioxidant properties,
either through their reducing capacities or their possible in-
fluence on intracellular redox states. These small molecule
bioactives can directly bind receptor tyrosine kinases and
alter their phosphorylation state to regulate multiple cell
signaling pathways (Fig. 5). Elevated levels of the EGFR and
HER-2 have been identified as common components of
multiple cancer types and appear to promote solid tumor
growth [200, 201]. EGFR inhibition is exhibited by multiple
polyphenols including resveratrol [202], quercetin [203],
curcumin [204], and green tea extracts [205]. HER-2 over-
expression in tumor cells is also attenuated by these bioac-
tives [206–208]. Fibroblast growth factors are involved in a
variety of cellular processes, such as tumor cell prolifera-
tion, drug resistance, and angiogenesis [209]. Oncogenic
alterations of RTK kinases including FGFR1, FGFR3, and
FGFR4 are inhibited by natural compounds [210–212].
Similarly, curcumin and chrysin block expression of recep-
tor d’origine nantais (RON) in tumor cells [213, 214]. The
product of the human SRC gene, c-Src, is found to be over-
expressed and highly activated in a wide variety of human
cancers [215]. It is also accompanied by elevated levels of
Abl [216] and JAK-2 kinases [217]. Interestingly, the over-
expression and translocation of oncogenic cytoplasmic
tyrosine kinases such as c-SRC [218], Abl [219], c-Met
[220] and JAK-2 [221, 222] are tempered by natural com-
pounds. Serine/threonine kinases, within the kinase family,
play vital roles regarding their involvement in human can-
cers. Akt, a crucial kinase modulates diverse cellular pro-
cesses involved in the regulation of cell survival, cell cycle
progression and cellular growth [223]. Up to date, more
than 50 proteins have been identified as the phosphoryl-
ation substrates of Akt. Resveratrol modulates expression
of Akt in breast [224], uterine [225], prostate [226, 227],
skin [228] and glioma cells [229]. It targets the kinases at
ATP-binding site competitively and reversibly [230, 231].
Furthermore, myricetin has been reported to target
Akt to inhibit cell transformation and proliferation by
directly binding to the ATP-binding site of Akt [232].
Similar effects are also exhibited by curcumin [233],
Fig. 5 Structures of key natural bioactives which pharmacologically modulate kinases
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quercetin [234, 235], green tea molecules [236], anthocy-
anins [237] and other polyphenols [238–240]. Hyper-
activity of cyclin-dependent kinases (CDKs) is one of the
key mechanisms underlying tumorigenesis [241]. The
overexpression of CDKs is inhibited by various small
molecule compounds [242–246]. Likewise, hyperactivity
of mTOR pathway is also downregulated by natural com-
pounds [229, 247–249]. The mTOR pathway is a critical
effector in cell-signaling pathways and is commonly
deregulated in human cancers. Furthermore, small mol-
ecule compounds also inhibit the activity of polo-like
and Aurora kinases [207, 210, 250, 251]. B-Raf kinases,
key kinases intimately involved in cancer cell prolifera-
tion [252], are also inhibited by natural plant com-
pounds such as curcumin, luteolin, quercetin and
ursolic acid [253, 254]. Finally, the overexpression of
oncogenic lipid kinases such as PI3K and SK1 is also
mitigated by small molecule bioactives. More than 30%
of various solid tumor types were recently found to
contain mutations in PI3K [255]. Well explored bio-
active molecules such as resveratrol [228], curcumin
[256], quercetin [235] and green tea polyphenols [257]
inhibit PI3K pathway. Similar to the parent compounds,
metabolites of bioactives also inhibit PI3K pathway
[258]. Sphingosine kinase 1 (SphK1) is also an import-
ant component of carcinogenesis as it converts the
proapoptotic lipids ceramide and sphingosine into the
anti-apoptotic lipid sphingosine-1-phosphate [259].
Inhibition of SphK1 is exhibited by few chelating bioac-
tives [260–262]. Oncogenic kinases are vital proteins that
couple extracellular signals with intracellular signaling
pathways, which contribute to all stages of cancer devel-
opment. Accumulated data reveals that plant compounds,
particularly polyphenols, exert anti-cancer effects through
acting on protein kinase signaling pathways. Many natural
bioactives bind directly to oncogenic protein kinases and
then alter their phosphorylation state, thus mitigating cell
signaling pathways in carcinogenesis processes.
Challenges and limitations
Despite numerous advances, scientists are still trying to
understand pathophysiology and application of kinase
inhibitors for therapeutic benefit in clinical oncology.
Kinase inhibition triggers a strong discerning pressure
for cells to acquire resistance to chemotherapy through
kinase mutations [263]. Thus, the treatment and path-
ology of cancer are further complicated by the plethora
of such mutations that occur in different kinases [264].
There are two types of chemotherapy resistance: de novo
resistance, which refers to the failure of an agent to pro-
duce any detectable response after initial treatment and
acquired resistance. Multiple mechanisms including the
targeted kinase, the structure of inhibitor, and the under-
lying genetic features of the tumor contribute to treatment
failure and both types of resistance. Acquired resistance
refers to the progression of a tumor that initially responds
to treatment and subsequently becomes resistant to treat-
ment despite continual administration of the inhibitor.
Interestingly, most of the kinase resistant cases fall into
the acquired resistant category. Treatment resistance asso-
ciated with kinase inhibitors is induced by changes in the
kinase gatekeeper residue as hydrophobic interactions on
this site are crucial for the binding affinity of the inhibitor
[265, 266]. Since a small gatekeeper residue allows an
inhibitor to access the “gated” hydrophobic regions of the
binding pocket, changes in this region hinder activity of
kinase inhibitors. The gatekeeper residue has no inter-
action with ATP but is usually in contact with Type I and
Type II kinase inhibitors and sterically impedes inhibitor
binding [98]. These mutations mainly lead to in the substi-
tution of one amino acid for another in the protein made
by a gene, thus conferring resistance to cell cycle termin-
ation and chemo drugs. A classic example is induction of
imatinib resistance due to gatekeeper mutations in Thr
315 (coded by ACT) in BCR-ABL kinase [254]. Other
examples of such gatekeeper mutations include T790
(EGFR) [267], G697R (FLT3) [268], BCR–ABL1 (T315I)
[269], PDGFRα (T674I) [270] and KIT (T670I) [271]
oncogenic mutations. In the case of the EGFR kinase, the
T790 M mutation induces resistance to quinazoline inhib-
itors by increasing affinity for the natural substrate ATP
[272]. It is one of the most common mutations in which
methionine substitutes for threonine at amino acid pos-
ition 790, conferring a growth advantage to cancer cells
alongside drug-resistant variant of the targeted kinase
[273]. Similarly, 20% of cases of acquired TKI resistance
involve amplification of the MET gene [274]. These events
thereby provide signalling redundancy and eliminate con-
sequences of clinical kinase inactivation. Furthermore, the
lipid modifying PI3K together with the Ras-Raf-MAPK
also undergoes several resistance-inducing mutations
[275]. Interestingly, these mutations cause a minute or no
change in kinase activity but confer inhibitor resistance to
kinase inhibitors [276]. An example includes gatekeeper
mutation T790 M in EGFR which causes gefitinib and
erlotinib resistance via hyper affinity for ATP [277, 278].
Overcoming gatekeeper-mutation induced drug-resistance
in the clinic is extremely difficult and requires structural
fine-tuning of the drug candidates. To surmount resist-
ance to inhibitors gefitinib and erlotinib, kinase inhibitors
that bind covalently to the ATP-binding site of EGFR are
been developed [117, 279]. Such next-generation EGFR
inhibitors selectively target the inhibitor-sensitizing muta-
tions and display an improved safety profile by sparing
wild-type EGFR activity in normal cells. A recent study
using chemical proteomics analyzed 243 clinically evalu-
ated kinase drugs and showed that some kinase inhibitors
are highly selective, especially KIs targeting mutant EGFR
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[108]. Likewise, G-loop mutations in ABL, p38α, FGFR1,
CK2α1, JNK3, AURORA-A, ROCK1 and CDK5 kinases
prompt oncogenic or drug-sensitizing mutations [280].
Another clinical challenge associated with kinase inhibi-
tors is variation in clinical results from combinations of
kinase inhibitors. Examples of clinical failure include com-
bined gefitinib and trastuzumab treatment in breast can-
cer, erlotinib and bevacizumab in renal cell carcinoma,
and cetuximab and bevacizumab in colorectal cancer.
Conversely, combinations of lapatinib and pertuzumab
with trastuzumab in breast cancer, and combination of
bevacizumab and erlotinib in NSCLC have exhibited clin-
ical success. Further, in some cases, the combinations of
kinase targeting agents reduced patient survival compared
with the treatment using single drug [281]. However, these
discrepancies are proposed due to misinterpretation of the
preclinical data, rather than a failure of the preclinical
model itself [282, 283]. Additionally, these preclinical
studies of drug combinations are probably biased towards
validating well-characterized targets thereby limiting their
ability to prioritize novel targets. Further, many kinase in-
hibitors are associated with toxicities and off-target effects
such as cardiotoxicity, hypertension, hypothyroidism, skin
reactions and proteinuria [284, 285]. Looking specifically,
inhibition of EGFR is associated with dermatological
problems, VEGFR inhibition with cardiotoxicity, HER2
and ALK inhibition with gastric irregularities and derma-
tological problems, and BCR-ABL inhibition causes
cytopenia, in addition to cardiotoxicity and cardiac com-
plications [286, 287]. Another challenge is in translating
RNAi therapy into drugs, particularly in kinase inhibition.
The majority of drug targets cannot be battered by shRNA
(or gene knockout) as most shRNAs cannot be replicated
by drugs since most proteins cannot be translated to ther-
apy [288]. Thus, clinical resistance to kinase inhibitors
remains the major limitation to kinase-based -therapies.
Resistance to chemotherapy has also been well recognized
as a significant challenge in oncology, a problem also
confronted by kinase inhibitors. Beyond the stated illustra-
tive examples, numerous other pathways outside the
scope of this review can influence the clinical activity of
kinase inhibitors.
Numerous follow-up strategies are being employed to
overcome the challenge of kinase inhibitor resistance.
A first approach is to develop inhibitors that can
tolerate diverse amino acids at the gatekeeper position
[289, 290]. A second approach is to target the kinase
with inhibitors that bind at alternative binding sites
[115, 291]. A third approach involves targeting other
pathways that may be required for kinase transform-
ation [292]. These approaches have been demonstrated
to work in cell line studies, and strategies are being
developed for their clinical use. However, it is also vital
to consider the possibility that multiple different
resistance mechanisms might develop concurrently in
patients, thereby challenging clinical ability to over-
come acquired resistance to kinase inhibitors.
Future developments
Even though only a small fraction of the kinome is currently
being targeted, kinase inhibitor drug discovery has pro-
gressed dramatically in the past decade. Clinical evaluation
of kinase inhibitors has shown that therapeutic responses
vary widely in individual patients and across patient popula-
tions, and seem to depend on many diverse factors. Many
new candidate molecules have entered clinical trials, and
much more are still at the preclinical stage. Most of the
current kinase inhibitor discoveries have developed through
rational drug design rather than through random screening
and analysis of structure-activity relationships. An important
strategy required for future development is to understand
the basis of unexpected toxicities related to kinase inhibitors.
Improvement in the documentation of toxicities of kinase
inhibitor would provide a valuable database for understand-
ing whether there are particular kinases of which inhibition
should be avoided or specific substructures that result in
problematic metabolites. This strategy will help to develop
kinases with better selectivity benefitting the vast patient
population. Also, there is a critical need for better ways to
monitor target kinase inhibition in humans using minimally
invasive techniques. This may include monitoring of cancer
biomarkers that may serve as benchmarks for the clinical
development of kinase inhibitors. The development of such
technologies will help to discover and eradicate tumors
using targeted kinase inhibition with minimal toxicities.
There is also an urgent need for developing more non-ATP-
competitive kinase inhibitors as the current collection of
kinase inhibitors is limited to ABL, IKK, AKT, CHK1, MEK,
SRC, IGF1R inhibitors [99, 293–296]. Furthermore, there is
need to develop sophisticated modeling of chemotherapy
resistance in response to kinase inhibitors. This will help to
overcome kinase resistance and allow for the systematic
application of combinations of kinase inhibitors. Further-
more, novel pre-clinical models are required to identify the
best cocktails of kinase inhibitors combined with natural
bioactives. Advanced high-throughput cell-based screening
using well-defined phosphorylation readouts should be
established. However, it may prove challenging to screen
and develop natural kinase inhibitors using the cellular read-
out only. It is also important to understand that kinase
inhibitors are not only important for the treatment of
cancer, but also help us better understand the physiological
roles of kinases. In the field of oncology, kinase inhibitors
are proving to be well tolerated compared with conventional
cytotoxic chemotherapeutic treatments. The future of
kinase-targeted therapeutics in cancer appears promising,
and implementation of these strategies will help to achieve
therapeutic advances and overcome treatment hindrances.
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Conclusions
By transferring the γ-phosphate from the ATP-cofactor
onto diverse substrates, kinases regulate key cellular func-
tions. As many human diseases result from mutations and
overexpression of kinases, this enzyme class symbolizes an
important targeted strategy for drug development. Kinases
also play indispensable roles in signaling pathways that
regulate tumor cell functions. Deregulation of kinases
leads to a variety of pathophysiological changes triggering
cancer cell proliferation and metastases. Hyperactivation
of kinases also increases anti-apoptotic effects. Currently,
about one-third of all protein targets under research in
the pharmaceutical industry are kinase-based. Kinase
inhibitors represent targeted therapy resultant of the
understanding of molecular genetics and molecular signal-
ing pathways. Most of the FDA-approved kinase inhibitors
target ATP binding site of kinase enzymes and display
therapeutic indications against tumorigenesis. This class
of therapeutics represents a transformation from conven-
tional chemotherapy to targeted cancer treatment. Kinase
inhibitors have overcome a major drawback of traditional
cancer treatment as it effectively discriminates between
normal non-malignant cells and rapidly proliferating
cancer cells. This leads to fewer off-target effects and low
toxicities in the cancer patient population. Kinase inhibi-
tors are also often useful in combination with cytotoxic
chemotherapy or radiation therapy. A vital challenge for
clinical use of kinase inhibitors in the prevention of drug-
resistant cancer stem cells. This phenomenon occurs due
to cellular pressure to compensate for the loss of function
of an important kinase. Pharmacogenomic factors includ-
ing gene polymorphisms also contribute to primary kinase
drug-resistance. Due to the clinical importance of kinase
inhibitors, multiple strategies are required to overcome
resistance mechanisms and develop more effective
targeted therapies. A key approach is to allosterically in-
duce and stabilize inactive kinase conformations. In the
future, scientific advances may eventually allow scientists
to combine mutagenesis screens through next generation
sequencing and proteomic techniques with the computa-
tional modeling of compound interactions with all
possible mutant variants of a targeted kinase. This will
lead to the development of well-tolerated kinase inhibitors
compared to traditional chemotherapeutic treatments.
Overall, kinase inhibitors represent a new and promising
approach to cancer therapy, one that is already providing
beneficial clinical effects.
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